Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
Avatar

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy: 2nd Gen ALK TKIs Alectinib & Brigatinib, and BFAST NGS Screening Workflow

By Xth Eurasian Hematology-Oncology Congress FEATURING Perran Fulden Yumuk
By Xth Eurasian Hematology-Oncology Congress FEATURING Perran Fulden Yumuk
0 views
March 18, 2021
Comments 0
Login to view comments. Click here to Login

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Lung
05:21
Xth Eurasian Hematology-Oncology Congress

Management of ALK+ NSCLC Through First and Subsequent Lines of Thera…

Feat. P. Yumuk
17:12
Xth Eurasian Hematology-Oncology Congress

Management of ALK+ NSCLC Through 1st and Subsequent Lines of Therapy…

Feat. P. Yumuk
20:50
Xth Eurasian Hematology-Oncology Congress

Sequencing Agents in the Management of EGFR+ NSCLC: TKI Optimal Trea…

Feat. M. Erman
08:26
Xth Eurasian Hematology-Oncology Congress

Sequencing Agents in the Management of EGFR+ NSCLC: Optimal 1st and …

Feat. M. Erman
05:02
Xth Eurasian Hematology-Oncology Congress

Anti-PD-1 / Anti-PD-L1 as Standard 2nd Line Treatment Improved OS in…

Feat. B. Uluc
14:47
Xth Eurasian Hematology-Oncology Congress

(DO NOT USE) Anti-PD-1 / Anti-PD-L1 in Newly Diagnosed Advanced NSCLC: Is …

Feat. B. Uluc
05:57
Xth Eurasian Hematology-Oncology Congress

1st, 2nd, 3rd Line & Maintenance IO Options in Locally Advanced …

Feat. B. Uluc